Although the medical relevance of the aforementioned cardiovascular chance factor alterations by tirzepatide will likely be assessed from the planned cardiovascular consequence examine SURPASS-CVOT ( "form":"scientific-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-analysis